Department of Surgery, The Tweed Hospital, Tweed Heads, NSW, 2485, Australia.
Faculty of Medicine, Bond University, Robina, QLD, Australia.
Tech Coloproctol. 2017 Oct;21(10):803-808. doi: 10.1007/s10151-017-1700-2. Epub 2017 Oct 28.
There is no consensus on the optimal dosage of botulinum toxin (BT) as a sphincter sparing alternative to lateral internal sphincterotomy for chronic anal fissure. The aim of this study was to assess the long-term efficacy of high-dose BT as well as the presence of incontinence following the treatment of chronic anal fissure at a single institution.
A retrospective case-control study was performed at a single institution over a 6-year period (2009-2014). Patients given high-dose (80-100 IU) BT were compared to low-dose (20-40 IU) case controls. Clinical notes were reviewed, and follow-up was carried out via a telephone questionnaire.
One hundred and fifty-eight patients were treated with BT injections within the study period (103 high dose; 55 low dose). The mean length of follow-up was 25 months (range 4-52 months). Classic posterior fissures with high anal tone were more prevalent in the low-dose group (40 vs 47%, p = 0.3). Patient satisfaction was higher in the high-dose group (90 vs 78%, p = 0.05). Long-term recurrence (6 months after the last treatment) was also lower (23 vs 53%, p = 0.0001) on multivariate analysis. No long-term incontinence was observed.
In this series, the recurrence rate post-BT injection was significantly lower in the high-dose group. There was no long-term incontinence. Further studies are needed to confirm our results.
对于慢性肛裂,作为外侧内括约肌切开术的括约肌保留替代方法,肉毒杆菌毒素(BT)的最佳剂量尚未达成共识。本研究旨在评估高剂量 BT 治疗慢性肛裂的长期疗效以及治疗后是否存在失禁。
在一家机构进行了为期 6 年(2009-2014 年)的回顾性病例对照研究。将接受高剂量(80-100IU)BT 的患者与低剂量(20-40IU)病例对照进行比较。回顾临床记录,并通过电话问卷进行随访。
在研究期间,158 例患者接受了 BT 注射治疗(高剂量 103 例;低剂量 55 例)。平均随访时间为 25 个月(范围 4-52 个月)。低位组更常见高肛门张力的经典后位肛裂(40%比 47%,p=0.3)。高剂量组的患者满意度更高(90%比 78%,p=0.05)。多变量分析显示,长期复发(最后一次治疗后 6 个月)也更低(23%比 53%,p=0.0001)。未观察到长期失禁。
在本系列中,高剂量组 BT 注射后的复发率明显较低。没有长期失禁。需要进一步的研究来证实我们的结果。